2024-01-26 12:47:12 ET
Summary
- Today, we take another look at Halozyme Therapeutics, Inc., which enhances drug delivery through its ENHANZE platform, earning royalties and milestone payouts from major drugmakers.
- Management has plans in place to more than double royalty revenues by FY2027 and the stock is a reasonable value in an overvalued market.
- An updated analysis of Halozyme Therapeutics follows in the paragraphs below.
Debt is the slavery of the free ." - Publilius Syrus.
It has been just over a year since I posted my last take on Halozyme Therapeutics, Inc. ( HALO ) . This name comes up occasionally in comments from Seeking Alpha followers, and it feels like it is time to circle back on this mid-cap biotech name. An updated analysis follows below....
Read the full article on Seeking Alpha
For further details see:
Halozyme Therapeutics: A Reasonable Value In An Overvalued market